Eye laser technology reimagined.
Glaucoma is a pressure problem.
The eye’s drain—the trabecular meshwork—stops draining, and pressure builds. That pressure can take vision, and it does not give it back. Glaucoma is the leading cause of irreversible blindness worldwide, and 178 million people live with glaucoma or ocular hypertension. 1 The first line of defense is often a daily drop, yet nearly half of patients stop taking their drops within the first year. For patients who need more, the next step may be laser or surgery. Today, laser procedures are performed about four times as often as glaucoma surgeries.1. Source: Market Scope, 2025 Glaucoma Surgical Device Market Report.
Introducing SoftLase™
SoftLase is a compact, multimodal, non-incisional laser platform under development for the everyday ophthalmic practice.
Thirty years ago, the femtosecond laser changed eye surgery. But the technology remained inside large, expensive systems requiring dedicated space, docking, and suction—limiting how broadly it could be used. SoftLase is being developed around a picosecond core and a new architecture for delivering and scanning the laser beam. Our design goals include short procedure times, a compact footprint, and a cost structure suited to routine ophthalmic practice.
Reimagining Glaucoma Care with Multiple Breakthrough Treatments
PicoLumen™
PicoLumen™ is being developed to create a small outflow channel using low pulse energy.
ThinMesh™
ThinMesh™ is being developed to remove a targeted portion of the trabecular meshwork while preserving the underlying layers.
SoftMesh™
SoftMesh™ is being developed to create micro-openings within the trabecular meshwork, with the goal of preserving the overall integrity of the tissue.
The Team
Christopher Horvath, PhD
Chief Executive Officer
Christopher Horvath, PhD is a laser physicist, technology innovator, and entrepreneur dedicated to solving complex challenges through practical innovation. With more than 100 patents, he began his ophthalmic career over 30 years ago by inventing and developing the first femtosecond laser for ophthalmology, successfully commercialized as the IntraLase® femtosecond laser system.
He went on to help shape modern ophthalmic laser technology with the PurePoint® (Alcon) retina laser and the KeLoTec™ femtosecond cataract system, later expanding into glaucoma with the design and development of the XEN® Gel Stent. As Founder and CEO of EyeX Solutions, Dr. Horvath leads the company’s technology and vision to deliver advanced laser platforms for the entire eye—beginning with breakthrough innovations in glaucoma treatment.
Prof. Herbert A. Reitsamer, MD
Prof. Herbert A. Reitsamer, MD, is Chairman of the Department of Ophthalmology and Director of Experimental Ophthalmology & Glaucoma Research at SALK/Paracelsus Medical University in Salzburg, Austria. An ophthalmologist, physiologist, and electrotechnical engineer by training, he is an internationally recognized expert in glaucoma and anterior segment surgery. His research has focused on aqueous dynamics, minimally invasive glaucoma surgery, experimental therapies, and clinical outcomes. Prof. Reitsamer is widely regarded for integrating clinical practice, research, and education, and for his leadership in advancing innovative treatment concepts that translate scientific discovery into improved patient care.
Medical Advisory Board
Ike Ahmed, MD
Toronto, Canada
Analisa Arosemena, MD
Miami, USA
Ian Pitha, MD
Salt Lake City, USA
Arsham Sheybani, MD
St. Louis, USA
Stay Updated on Our Journey
Thirty years ago, the femtosecond laser changed ophthalmology. We believe picosecond technology can change it again.